MedTrace Logo

Autologous Immune Cell Therapy in Combination With LHRH-a in Patients With mCRPC

NCT03085966 · Status: UNKNOWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2017-03-21

No results posted yet for this study

Summary

Study of autologous immune cell therapy in combination with the luteinizing hormone releasing hormone agonists (LHRH-a) in patients with metastatic castration-resistant prostate cancer

Conditions

Interventions

BIOLOGICAL

autologous immune cell therapy

Luteinizing Hormone Releasing Hormone Agonists (LHRH-a) and Autologous dendritic cells (DC) and central memory T cells (Tcm cells)

Sponsors & Collaborators

  • Fudan University

    collaborator OTHER

  • Shanghai AbelZeta Ltd.

    lead INDUSTRY

Principal Investigators

  • Dingwei Ye · Fudan University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-02-27
Primary Completion
2019-10-27
Completion
2019-12-27

Countries

  • China

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03085966 on ClinicalTrials.gov